Method Suitability: Bacteriostasis and Fungistasis Testing in Microbiology
What Is Bacteriostasis and Fungistasis Testing?
Bacteriostasis and fungistasis testing is a method suitability procedure that verifies a microbiological test method can accurately detect bacteria and fungi in a specific product sample without interference from the product itself. It is performed as a prerequisite validation step before conducting sterility testing (USP <71>, Ph. Eur. 2.6.1) or microbial limits testing (USP <61>, <62>, Ph. Eur. 2.6.12, 2.6.13).
This testing is mandatory across the pharmaceutical, biotechnology, medical device, and personal care industries for any product that undergoes microbiological testing as part of its quality release or regulatory submission.
Why Bacteriostasis/Fungistasis Testing Is Required
Many pharmaceutical products contain ingredients—antimicrobial preservatives, surfactants, antibiotics, antifungal agents, pH extremes, or organic solvents—that can inhibit the growth of test microorganisms introduced during microbiological testing. If such inhibition is not detected and corrected, a contaminated product may falsely pass sterility testing or microbial limits testing—a serious patient safety failure.
Method suitability testing demonstrates that the intended microbiological test method, using the defined sample quantity, dilution, or membrane filtration procedure, does not suppress or inhibit microbial growth below the threshold of detection.
Regulatory Requirements
|
Regulation |
Requirement |
|
USP <71> (Sterility Tests) |
Method suitability must be performed for each product formulation |
|
USP <61> (TAMC/TYMC) |
Method suitability (growth promotion and suitability of counting method) |
|
USP <62> (Specified organisms) |
Suitability of test methods for each specified organism |
|
Ph. Eur. 2.6.1 / 2.6.12 |
Equivalent European Pharmacopoeia requirements |
|
ISO 11737-2 |
Sterility testing of medical devices |
|
FDA 21 CFR 211.167 |
Special testing requirements including sterility |
Test Organisms Used in Method Suitability Testing
Pharmacopoeial method suitability testing uses a defined panel of reference organisms representative of bacteria and fungi:
For bacteriostasis:
- Staphylococcus aureus ATCC 6538
- Bacillus subtilis ATCC 6633
- Pseudomonas aeruginosa ATCC 9027
- Clostridium sporogenes ATCC 19404 (for anaerobic sterility testing)
For fungistasis:
- Candida albicans ATCC 10231
- Aspergillus brasiliensis ATCC 16404
Each organism is inoculated into the test system (with and without product) at a defined challenge level (typically not more than 100 CFU per test unit).
Method Suitability Test Procedure
- Prepare the product sample using the intended microbiological test procedure (direct inoculation, membrane filtration with defined rinse volume, or dilution)
- Inoculate with a known, low number of the test organism (< 100 CFU per inoculated test vessel or membrane)
- Incubate at appropriate temperature and duration per the pharmacopoeia
- Compare growth in inoculated product-containing test vessels to inoculated negative controls (without product)
- Pass criterion: Growth is observed in the product-containing test (indicating no inhibition of microbial growth)
Corrective Actions When Inhibition Is Detected
If bacteriostasis or fungistasis is detected (no growth in product-containing test), the test method must be modified to eliminate inhibition:
- Increase the volume of rinsing liquid during membrane filtration
- Increase dilution of the product
- Add neutralizing agents (e.g., polysorbate 80 for surfactant/antimicrobial neutralization; lecithin; sodium thiosulfate)
- Use alternative growth media
The modified method is re-validated until all test organisms demonstrate growth recovery in the presence of the product.
Why Choose Infinita Lab for Method Suitability and Microbiological Testing?
Infinita Lab provides comprehensive microbiological method suitability testing (bacteriostasis/fungistasis), sterility testing, and microbial limits testing through its nationwide accredited pharmaceutical microbiology laboratory network. Our cGMP-compliant laboratories operate under rigorous quality systems with full documentation for regulatory submissions.
Looking for a trusted partner to achieve your research goals? Schedule a meeting with us, send us a request, or call us at (888) 878-3090 to learn more about our services and how we can support you. Request a Quote
Frequently Asked Questions (FAQs)
How often must bacteriostasis/fungistasis method suitability be re-performed? Per USP, method suitability must be performed when a new product formulation is introduced, when the test method changes (different membrane filter, different rinse volume, different medium), when the product formulation changes, or when there is reason to believe that a product change may affect its inhibitory properties. It does not need to be repeated with every lot release if the method and formulation are unchanged.
What is the "not more than 100 CFU" inoculation requirement, and why is a low challenge level specified? The low inoculation level (ideally not more than 100 CFU, often 10–100 CFU) is specified so that bacteriostasis/fungistasis detection is sensitive. If a high inoculum (thousands of CFU) were used, partial inhibition might still permit some growth that would appear as a "pass"—masking true inhibitory activity. At low inoculum levels, even mild inhibition causes complete suppression, which is detected as a failure.
Can bacteriostasis/fungistasis testing be performed on medical devices? Yes. ISO 11737-2 requires method suitability testing for sterility testing of medical devices. The challenge organism panel includes aerobic and anaerobic bacteria and fungi. For devices tested by direct inoculation of product or rinsate, inhibitory extractables from device materials must be neutralized or removed before testing.
What is the difference between bacteriostasis and antimicrobial effectiveness testing? Bacteriostasis testing verifies that the test method itself is not inhibitory—it is a quality control procedure for the microbiological test. Antimicrobial effectiveness testing (USP <51>) deliberately evaluates the ability of a product's preservative system to prevent microbial growth—it is a product performance test. They use the same test organisms but have opposite objectives.
What neutralizing agents are used to counteract common pharmaceutical antimicrobial preservatives in method suitability testing? Common neutralizing agents include: polysorbate 80 (Tween 80) for quaternary ammonium compounds and parabens; lecithin combined with polysorbate 80 for broad-spectrum neutralization; sodium thiosulfate for iodine and mercury-based preservatives; L-histidine for formaldehyde; and dilution with specific media formulations (SCDM, TSB with Tween and lecithin) that provide a buffered neutralization environment.
